TI
ARQT icon

Trexquant Investment’s Arcutis Biotherapeutics ARQT Stock Holding History

Trexquant Investment’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,042
Closed -$402K – 1883
2026
Q1 		$402K Buy
+17,042
New +$435K ﹤0.01% 1527
2025
Q4 		– Sell
-21,590
Closed -$407K – 1569
2025
Q3 		$407K Buy
+21,590
New +$340K ﹤0.01% 1366
2025
Q1 		– Sell
-57,658
Closed -$803K – 1538
2024
Q4 		$803K Sell
57,658
-32,546
-36% -$357K 0.01% 1165
2024
Q3 		$839K Sell
90,204
-577,055
-86% -$5.69M 0.01% 1101
2024
Q2 		$6.21M Buy
667,259
+304,390
+84% +$2.75M 0.09% 341
2024
Q1 		$3.6M Buy
+362,869
New +$2.71M 0.07% 426
2023
Q4 		– Sell
-58,568
Closed -$311K – 1408
2023
Q3 		$311K Buy
+58,568
New +$498K 0.01% 1209
2022
Q2 		– Sell
-18,372
Closed -$354K – 1505
2022
Q1 		$354K Buy
+18,372
New +$311K 0.02% 921

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Trexquant Investment's ARQT Position: Q2 2026 in Review

Trexquant Investment sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 17,042 shares — an estimated $402K sold.

Trexquant Investment first reported a position in ARQT in Q1 2022 and held it in 8 quarters. The position peaked at $6.21M in Q2 2024. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Trexquant Investment reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Trexquant Investment sold 17,042 Arcutis Biotherapeutics shares in Q2 2026, an estimated $402K.
  • Trexquant Investment first reported a position in Arcutis Biotherapeutics in Q1 2022 and held it in 8 quarters.
  • Trexquant Investment's Arcutis Biotherapeutics position peaked at $6.21M in Q2 2024.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.